卵巣がん治療薬の世界市場レポート 2024

卵巣がん治療薬の市場規模は、今後数年間で急速に成長すると予想されています。 2028年には14.8%の年間複合成長率（CAGR）で89億4,000万米ドルに成長すると予想されます。予測期間中に予想される成長は、高齢者人口の拡大と医薬品の研究開発支出の増加に関連しています。この期間に予想される主な動向としては、抗体薬物複合体のイントロダクション、収益と製品提供の強化を目的とした提携とパートナーシップ、卵巣がんの埋め込み型製薬工場への戦略的焦点などが挙げられます。

卵巣がんの罹患率の増加は、卵巣がん治療薬市場の成長の主な原動力です。卵巣がんは、女性で8番目に多く診断されるがんであり、世界的には18番目に罹患率の高いがんです。米国がん協会の卵巣がん統計で報告されているように、2023年には米国だけで推定19,710人の新たながん症例と13,270人の関連死亡が予想されています。この世界の卵巣がん罹患率の増加は、卵巣がん治療薬市場の拡大に大きく貢献しています。

卵巣がんへの対処を目的とした政府の取り組みと資金提供により、卵巣がん治療薬市場の成長がさらに促進されると予想されます。政府の取り組みには、公共サービスと経済の向上に貢献するプロジェクトで選ばれた団体に財政的支援を提供することが含まれます。このような支援は、患者の生活の質と生存率の向上を目的とした卵巣がん調査において重要な役割を果たしています。たとえば、2021年 7月、米国に本拠を置く政府機関である国立がん研究所は、特に卵巣がんの調査に1億3,470万米国という多額の予算を割り当てました。したがって、政府の取り組みからの支援と資金提供が、卵巣がん治療薬市場の成長を促進する重要な要因となります。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

• 高インフレが市場に与える影響
• ウクライナ・ロシア戦争が市場に与える影響
• COVID-19による市場への影響

第5章 世界市場規模と成長

• 世界の市場促進要因と抑制要因
  • 市場促進要因
  • 市場抑制要因
• 世界の市場規模実績と成長、2018年～2023年
• 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 市場セグメンテーション

• 世界の卵巣がん治療薬市場、腫瘍タイプ別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 上皮性卵巣がん
• 卵巣の悪性度の低い腫瘍
• 胚細胞腫瘍
• 性索間質腫瘍
• 世界の卵巣がん治療薬市場、薬剤タイプ別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• アルキル化剤
• 有糸分裂阻害剤
• 抗リウマチ薬
• 抗乾癬薬
• VEGF/VEGFR阻害剤
• PARP阻害剤
• 抗悪性腫瘍薬
• 他の種類の薬剤
• 世界の卵巣がん治療薬市場、流通チャネル別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 病院薬局
• ドラッグストア
• その他の流通チャネル

第7章 地域および国の分析

• 世界の卵巣がん治療薬市場、地域別、実績および予測、2018-2023年、2023-2028年、2033年
• 世界の卵巣がん治療薬市場、国別、実績および予測、2018-2023、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 卵巣がん治療薬市場の競合情勢
• 卵巣がん治療薬市場の企業プロファイル
  • AstraZeneca plc
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline plc
  • Amgen Inc
  • Bristol-Myers Squibb Company

第31章 その他の大手および革新的な企業

• Clovis Oncology
• Pfizer, Inc.
• Novartis AG
• Pharma Mar SA
• Vivesto
• BDR Pharmaceutical
• GLS Pharma
• Eisai Co., Ltd.
• Denovo Biopharma
• Jiangsu Hengrui Medicine
• BeiGene
• Innovent Biologics
• Zai Lab
• EUSA Pharma
• Recordati ,

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと可能性の分析

第36章 付録

Ovarian cancer drugs are pharmaceuticals specifically designed for the treatment of ovarian cancer, a condition arising from abnormal cell growth in the ovaries. This sector encompasses establishments engaged in the production of drugs utilized in ovarian cancer treatment through chemotherapy, radiation, and surgery. Notable examples of ovarian cancer drugs include Doxorubicin Hydrochloride Liposome, Evacet (Doxorubicin Hydrochloride Liposome), Cytoxan (Cyclophosphamide), Paraplat (Carboplatin), Taxol (Paclitaxel), Neosar (Cyclophosphamide), among others.

Ovarian cancer drugs target different types of tumors, namely epithelial ovarian cancer, germ cell ovarian cancer, and stromal cell ovarian cancer. Epithelial ovarian cancer is the most prevalent type, accounting for 90% of ovarian tumors. This form originates in the epithelial layer that covers the ovary. The diverse categories of drugs for ovarian cancer treatment include alkylating agents, mitotic inhibitors, VEGF/VEGF inhibitors, PARP inhibitors, among others. These drugs are distributed through various channels such as hospital pharmacies, drug stores, and others.

The ovarian cancer drugs market research report is one of a series of new reports from The Business Research Company that provides ovarian cancer drugs market statistics, including ovarian cancer drugs industry global market size, regional shares, competitors with an ovarian cancer drugs market share, detailed ovarian cancer drugs market segments, market trends and opportunities, and any further data you may need to thrive in the ovarian cancer drugs industry. This ovarian cancer drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The ovarian cancer drugs market size has grown rapidly in recent years. It will grow from $4.48 billion in 2023 to $5.16 billion in 2024 at a compound annual growth rate (CAGR) of 15.0%. The historical period's growth can be credited to an increase in the occurrence of ovarian cancer, the emergence of new medications and therapies, elevated government initiatives for the treatment of ovarian cancer, and a rise in healthcare expenditure.

The ovarian cancer drugs market size is expected to see rapid growth in the next few years. It will grow to $8.94 billion in 2028 at a compound annual growth rate (CAGR) of 14.8%. The anticipated growth in the forecast period is linked to the expanding geriatric population and a rise in pharmaceutical research and development expenditure. Key trends expected during this period include the introduction of antibody-drug conjugates, collaborations and partnerships aimed at enhancing revenues and product offerings, and a strategic focus on implanted drug factories for ovarian cancer.

The increasing prevalence of ovarian cancer is a key driver of growth in the ovarian cancer drugs market. Ovarian cancer ranks as the eighth most commonly diagnosed cancer in women and the 18th most prevalent cancer globally. In 2023, as reported by the American Cancer Society in their Ovarian Cancer Statistics, an estimated 19,710 new cases of cancer and 13,270 related deaths were anticipated in the USA alone. This rise in ovarian cancer incidence worldwide contributes significantly to the expansion of the ovarian cancer drugs market.

Government initiatives and funding aimed at addressing ovarian cancer are expected to further propel the growth of the ovarian cancer drugs market. Government initiatives involve providing financial support to selected entities with projects contributing to the improvement of public services and the economy. Such support plays a crucial role in ovarian cancer research, aiming to enhance the quality of life and survival rates for patients. For instance, in July 2021, the National Cancer Institute, a US-based government agency, allocated a significant sum of 134.7 million US Dollars specifically for ovarian cancer research. Consequently, the support and funding from government initiatives are key factors driving the growth of the ovarian cancer drugs market.

Pharmaceutical companies engaged in drug manufacturing are increasingly embracing innovation, particularly in the development of combination drugs for treating ovarian cancer. Combination drugs, composed of two or more active pharmaceutical ingredients (APIs) consolidated into a single dosage form, are designed to address complex medical conditions. Companies in the ovarian cancer drugs market are actively investing in research and development to create innovative products such as combination drugs. These endeavors aim to reduce manufacturing costs, enhance compliance and efficiency, improve medication concordance, boost profitability, and minimize side effects. Notably, Roche's FDA-approved blockbuster drug Avastin (bevacizumab) is an example of a combination drug, featuring ingredients such as carboplatin and paclitaxel, used for the treatment of advanced-stage (III or IV) ovarian cancer.

Major players in the ovarian cancer drug market are strategically focusing on producing innovative drugs, including antibody-drug conjugates, to drive market revenues. Antibody-drug conjugates (ADCs) represent a biopharmaceutical drug category that combines a monoclonal antibody (mAb) with a cytotoxic drug through a chemical linker. For instance, in November 2022, the US-based biotechnology company ImmunoGen, Inc. introduced Mirvetuximab soravtansine-gynx. This drug targets the overexpressed FRα protein on the surface of many cancer cells, including ovarian cancer cells. The antibody delivers the microtubule inhibitor soravtansine to the cancer cells, disrupting their mitosis and causing cell death. This ADC shows promise as a new treatment for patients with folate receptor alpha-positive, platinum-resistant ovarian cancer. It represents the first ADC approved for this type of cancer and has demonstrated positive outcomes in clinical trials.

In September 2021, the Germany-based biopharmaceutical company Boehringer Ingelheim acquired Abexxa Biologics for an undisclosed amount. This strategic acquisition expands Boehringer Ingelheim's oncology portfolio by incorporating Abexxa's technology and antibody-based drugs for cancer treatment. Abexxa Biologics specializes in the development of cancer drugs, immuno-oncology, and advanced precision medicines for various cancer types, including ovarian cancer drugs.

Major companies operating in the ovarian cancer drugs market report are AstraZeneca PLC, F. Hoffmann-La Roche AG, GlaxoSmithKline PLC, Amgen Inc., Bristol-Myers Squibb Company, Clovis Oncology, Pfizer, Inc., Novartis AG, Pharma Mar SA, Vivesto, BDR Pharmaceutical, GLS Pharma, Eisai Co., Ltd., Denovo Biopharma, Jiangsu Hengrui Medicine, BeiGene, Innovent Biologics, Zai Lab , EUSA Pharma, Recordati , NEUCA, Farmacol, Polska Grupa Farmaceutyczna, Polpharma, TZMO, Msd Sanofi, Gilead Sciences , Johnson & Johnson, Merck & Co, AbbVie Inc., Aa Pharma In, Aaladin Superior Cleaning Systems Ltd., Accel Pharma Inc., EMS Pharma, Eurofarma, Neo Quimica, Mantecorp Farmasa , Abbott Laboratories Bayer , Laboratorio Elea Phoenix , Laboratorios Ac Farma , Teva , Monte Verde, Gador, Spimaco, Tabuk Pharmaceuticals, Jamjoom Pharma, Abcon International L.L.C., Adcan Pharma , Regal Pharmaceuticals Limited

North America was the largest region in the ovarian cancer drugs market in 2023. Middle East is expected to be the fastest-growing region in the global ovarian cancer drugs market share during the forecast period. The regions covered in the ovarian cancer drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the ovarian cancer drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain

The ovarian cancer drugs market consists of sales of Paclitaxel, Cisplatin, Adriamycin PFS (Doxorubicin Hydrochloride), Carboplatin, Cyclophosphamide, and Platinol (Cisplatin). Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Ovarian Cancer Drugs Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on ovarian cancer drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for ovarian cancer drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The ovarian cancer drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

• 1) By Tumor Type: Epithelial Ovarian Cancer; Germ Cell Ovarian Cancer; Stromal Cell Ovarian Cancer
• 2) By Drug Type: Alkylating Agents; Mitotic Inhibitors; VEGF/VEGFR inhibitors; PARP inhibitors; Other Drug Types
• 3) By Distribution Channel: Hospital Pharmacies; Drug Stores; Other Distribution Channels
• Companies Mentioned: AstraZeneca plc; F. Hoffmann-La Roche AG; GlaxoSmithKline plc; Amgen Inc; Bristol-Myers Squibb Company
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Ovarian Cancer Drugs Market Characteristics

3. Ovarian Cancer Drugs Market Trends And Strategies

4. Ovarian Cancer Drugs Market - Macro Economic Scenario

• 4.1. Impact Of High Inflation On The Market
• 4.2. Ukraine-Russia War Impact On The Market
• 4.3. COVID-19 Impact On The Market

5. Global Ovarian Cancer Drugs Market Size and Growth

• 5.1. Global Ovarian Cancer Drugs Market Drivers and Restraints
  • 5.1.1. Drivers Of The Market
  • 5.1.2. Restraints Of The Market
• 5.2. Global Ovarian Cancer Drugs Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
• 5.3. Global Ovarian Cancer Drugs Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Ovarian Cancer Drugs Market Segmentation

• 6.1. Global Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Epithelial Ovarian Cancer
• Ovarian Low Malignant Potential Tumor
• Germ Cell Tumor
• Sex Cord-Stromal Tumor
• 6.2. Global Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Alkylating Agents
• Mitotic Inhibitors
• Antirheumatics
• Antipsoriatics
• VEGF/VEGFR inhibitors
• PARP inhibitors
• Antineoplastics
• Other Drug Types
• 6.3. Global Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Hospital Pharmacies
• Drug Stores
• Other Distribution Channels

7. Ovarian Cancer Drugs Market Regional And Country Analysis

• 7.1. Global Ovarian Cancer Drugs Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 7.2. Global Ovarian Cancer Drugs Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Ovarian Cancer Drugs Market

• 8.1. Asia-Pacific Ovarian Cancer Drugs Market Overview
• Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.3. Asia-Pacific Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.4. Asia-Pacific Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Ovarian Cancer Drugs Market

• 9.1. China Ovarian Cancer Drugs Market Overview
• 9.2. China Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.3. China Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.4. China Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Ovarian Cancer Drugs Market

• 10.1. India Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.2. India Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.3. India Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Ovarian Cancer Drugs Market

• 11.1. Japan Ovarian Cancer Drugs Market Overview
• 11.2. Japan Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.3. Japan Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.4. Japan Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Ovarian Cancer Drugs Market

• 12.1. Australia Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.2. Australia Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.3. Australia Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Ovarian Cancer Drugs Market

• 13.1. Indonesia Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.2. Indonesia Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.3. Indonesia Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Ovarian Cancer Drugs Market

• 14.1. South Korea Ovarian Cancer Drugs Market Overview
• 14.2. South Korea Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.3. South Korea Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.4. South Korea Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Ovarian Cancer Drugs Market

• 15.1. Western Europe Ovarian Cancer Drugs Market Overview
• 15.2. Western Europe Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.3. Western Europe Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.4. Western Europe Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Ovarian Cancer Drugs Market

• 16.1. UK Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.2. UK Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.3. UK Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Ovarian Cancer Drugs Market

• 17.1. Germany Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.2. Germany Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.3. Germany Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Ovarian Cancer Drugs Market

• 18.1. France Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.2. France Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.3. France Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Ovarian Cancer Drugs Market

• 19.1. Italy Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.2. Italy Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.3. Italy Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Ovarian Cancer Drugs Market

• 20.1. Spain Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.2. Spain Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.3. Spain Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Ovarian Cancer Drugs Market

• 21.1. Eastern Europe Ovarian Cancer Drugs Market Overview
• 21.2. Eastern Europe Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.3. Eastern Europe Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.4. Eastern Europe Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Ovarian Cancer Drugs Market

• 22.1. Russia Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.2. Russia Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.3. Russia Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Ovarian Cancer Drugs Market

• 23.1. North America Ovarian Cancer Drugs Market Overview
• 23.2. North America Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.3. North America Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.4. North America Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Ovarian Cancer Drugs Market

• 24.1. USA Ovarian Cancer Drugs Market Overview
• 24.2. USA Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.3. USA Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.4. USA Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Ovarian Cancer Drugs Market

• 25.1. Canada Ovarian Cancer Drugs Market Overview
• 25.2. Canada Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.3. Canada Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.4. Canada Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Ovarian Cancer Drugs Market

• 26.1. South America Ovarian Cancer Drugs Market Overview
• 26.2. South America Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.3. South America Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.4. South America Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Ovarian Cancer Drugs Market

• 27.1. Brazil Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.2. Brazil Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.3. Brazil Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Ovarian Cancer Drugs Market

• 28.1. Middle East Ovarian Cancer Drugs Market Overview
• 28.2. Middle East Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.3. Middle East Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.4. Middle East Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Ovarian Cancer Drugs Market

• 29.1. Africa Ovarian Cancer Drugs Market Overview
• 29.2. Africa Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.3. Africa Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.4. Africa Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Ovarian Cancer Drugs Market Competitive Landscape And Company Profiles

• 30.1. Ovarian Cancer Drugs Market Competitive Landscape
• 30.2. Ovarian Cancer Drugs Market Company Profiles
  • 30.2.1. AstraZeneca plc
    • 30.2.1.1. Overview
    • 30.2.1.2. Products and Services
    • 30.2.1.3. Strategy
    • 30.2.1.4. Financial Performance
  • 30.2.2. F. Hoffmann-La Roche AG
    • 30.2.2.1. Overview
    • 30.2.2.2. Products and Services
    • 30.2.2.3. Strategy
    • 30.2.2.4. Financial Performance
  • 30.2.3. GlaxoSmithKline plc
    • 30.2.3.1. Overview
    • 30.2.3.2. Products and Services
    • 30.2.3.3. Strategy
    • 30.2.3.4. Financial Performance
  • 30.2.4. Amgen Inc
    • 30.2.4.1. Overview
    • 30.2.4.2. Products and Services
    • 30.2.4.3. Strategy
    • 30.2.4.4. Financial Performance
  • 30.2.5. Bristol-Myers Squibb Company
    • 30.2.5.1. Overview
    • 30.2.5.2. Products and Services
    • 30.2.5.3. Strategy
    • 30.2.5.4. Financial Performance

31. Ovarian Cancer Drugs Market Other Major And Innovative Companies

• 31.1. Clovis Oncology
• 31.2. Pfizer, Inc.
• 31.3. Novartis AG
• 31.4. Pharma Mar SA
• 31.5. Vivesto
• 31.6. BDR Pharmaceutical
• 31.7. GLS Pharma
• 31.8. Eisai Co., Ltd.
• 31.9. Denovo Biopharma
• 31.10. Jiangsu Hengrui Medicine
• 31.11. BeiGene
• 31.12. Innovent Biologics
• 31.13. Zai Lab
• 31.14. EUSA Pharma
• 31.15. Recordati ,

32. Global Ovarian Cancer Drugs Market Competitive Benchmarking

33. Global Ovarian Cancer Drugs Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Ovarian Cancer Drugs Market

35. Ovarian Cancer Drugs Market Future Outlook and Potential Analysis

• 35.1 Ovarian Cancer Drugs Market In 2028 - Countries Offering Most New Opportunities
• 35.2 Ovarian Cancer Drugs Market In 2028 - Segments Offering Most New Opportunities
• 35.3 Ovarian Cancer Drugs Market In 2028 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer